Registered Malawi · PMRA

PENSTREP 20/25 COMBINATION PRODUCT INJECTION

PROCAINE PENICILLIN G BP, DIHYDROSTREPTOMYCIN BASE EUR PH

PMPB/PL340/16 INJECTION sensory organs INN generic

What it does

Dihydrostreptomycin is an antibiotic used to treat certain bacterial infections.

Commonly used for: tuberculosis (TB), bacterial infections

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
PMPB/PL340/16
Registration date
01/07/2007
Expiry date
30/06/2008
Status
Registered
Active ingredient
PROCAINE PENICILLIN G BP, DIHYDROSTREPTOMYCIN BASE EUR PH
Dosage form
INJECTION
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
S01AA - Antibiotics
Drug group
SENSORY ORGANS
RxNorm RxCUI
1549540
Manufacturer / MAH
-
Applicant / LTR
-
Country of origin
-

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:41 · updated 2026-09-15 04:32:43

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.

About dihydrostreptomycin

Dihydrostreptomycin is an antibiotic used to treat certain bacterial infections.

What it treats

  • tuberculosis (TB)
  • bacterial infections

How it works

It fights bacteria by stopping their growth and reproduction.

Who it's for

This medicine is for adults and children with specific bacterial infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About eur

Eur is a medication used to treat various health conditions.

How it works

Eur works by affecting certain processes in the body to help improve symptoms of specific conditions.

Who it's for

Eur is prescribed for patients with specific health issues as determined by a healthcare provider.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About penicillin

Penicillin is an antibiotic used to treat various bacterial infections.

What it treats

  • bacterial infections
  • pneumonia
  • strep throat
  • skin infections

How it works

Penicillin works by stopping the growth of bacteria, helping the body fight off the infection.

Who it's for

It is suitable for people who have bacterial infections that are known to respond to penicillin.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About procaine

Procaine is a medication often used as a local anesthetic to numb specific areas of the body during medical procedures.

What it treats

  • numbing during surgery
  • to relieve pain in specific areas

How it works

Procaine works by blocking nerve signals in the area where it is applied, preventing feelings of pain.

Who it's for

Procaine is for patients needing local anesthesia for minor surgical procedures or pain relief.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: dihydrostreptomycin

BNF-referenced

Dihydrostreptomycin is an aminoglycoside antibiotic that is used primarily to treat infections caused by certain bacteria. It is particularly effective against Mycobacterium tuberculosis, making it valuable in the treatment of tuberculosis. Dihydrostreptomycin works by inhibiting bacterial protein synthesis, which is essential for bacterial growth and replication.

Indications

  • Tuberculosis
  • Bacterial infections caused by susceptible strains of Mycobacteria
  • Severe infections caused by Gram-negative bacteria

Dosage

Children: Refer to BNF for Children for appropriate pediatric dosing recommendations.

Adults: Refer to BNF for specific dosing guidance, as it may vary based on the indication and patient condition.

Mechanism of action

Dihydrostreptomycin binds to the 30S ribosomal subunit of bacteria, interfering with the initiation complex and causing misreading of the mRNA. This action leads to the production of nonfunctional proteins and ultimately results in bacterial cell death.

Pharmacodynamics

Dihydrostreptomycin exhibits concentration-dependent bactericidal activity against a variety of Gram-negative and some Gram-positive bacteria. Its efficacy is influenced by the peak concentration achieved relative to the minimum inhibitory concentration (MIC) of the organism.

Pharmacokinetics

Dihydrostreptomycin is administered parenterally due to poor oral absorption. It is widely distributed in body tissues and fluids, but does not penetrate well into the central nervous system. The drug is primarily eliminated by renal excretion, and its half-life can be prolonged in patients with renal impairment.

Contra-indications

  • Hypersensitivity to dihydrostreptomycin or other aminoglycosides
  • Severe renal impairment
  • Myasthenia gravis

Adverse effects

  • Ototoxicity, including hearing loss and vestibular dysfunction
  • Nephrotoxicity, particularly with high doses or prolonged therapy
  • Neuromuscular blockade
  • Allergic reactions, including rash and anaphylaxis

Interactions

  • Increased risk of nephrotoxicity with other nephrotoxic agents such as vancomycin, amphotericin B, and non-steroidal anti-inflammatory drugs (NSAIDs)
  • Potentially enhanced neuromuscular blockade with neuromuscular blockers

Precautions

  • Use with caution in patients with pre-existing renal impairment
  • Monitor renal function regularly during therapy
  • Assess hearing function prior to and during treatment

Pregnancy

Dihydrostreptomycin is categorized as a category D drug. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Dihydrostreptomycin is excreted in breast milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Formulations

  • Injection solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: penicillin

BNF-referenced

Penicillin is a group of antibiotics that are widely used to treat bacterial infections. It works by inhibiting the synthesis of bacterial cell walls, leading to cell lysis and death. Penicillin is effective against a variety of gram-positive bacteria and some gram-negative bacteria, making it a cornerstone in the treatment of infections such as pneumonia, streptococcal infections, and syphilis.

Indications

  • Bacterial infections
  • Pneumonia
  • Streptococcal infections
  • Syphilis
  • Meningitis
  • Endocarditis
  • Skin infections

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on the type of penicillin and indication.

Adults: Refer to the BNF for specific dosing recommendations based on the type of penicillin and indication.

Mechanism of action

Penicillin targets penicillin-binding proteins (PBPs) located inside the bacterial cell wall. By binding to these proteins, penicillin disrupts the transpeptidation process, which is essential for cell wall structural integrity. This results in weakened cell walls, causing osmotic instability and ultimately leading to cell lysis and death.

Pharmacodynamics

Penicillin exhibits bactericidal activity, meaning that it kills bacteria rather than merely inhibiting their growth. Its effectiveness is generally dependent on the growth phase of the bacteria, as it is most active against actively dividing cells. The spectrum of activity varies among different penicillins, with some being more effective against specific bacterial strains.

Pharmacokinetics

Penicillin is primarily absorbed in the gastrointestinal tract, with its bioavailability varying depending on the specific type of penicillin. It is primarily excreted by the kidneys, with a half-life that typically ranges from 30 minutes to 2 hours, depending on the formulation. Dosage adjustments may be necessary in patients with renal impairment to prevent accumulation and toxicity.

Contra-indications

  • History of hypersensitivity to penicillins
  • Severe allergic reactions to beta-lactam antibiotics

Adverse effects

  • Allergic reactions such as rash, urticaria, and anaphylaxis
  • Gastrointestinal disturbances including nausea, vomiting, and diarrhea
  • Superinfection due to alteration of normal flora
  • Hematologic reactions such as leukopenia, thrombocytopenia

Interactions

  • valproate+penicillins: Severe (increases risk of adverse effects)
  • allopurinol+penicillins: Unknown (increases risk of skin rash)
  • leflunomide+penicillins: Unknown (increases exposure)
  • nitisinone+penicillins: Unknown (increases exposure)
  • penicillins+phenindione: Unknown (increases risk of bleeding events)
  • teriflunomide+penicillins: Unknown (increases exposure)

Precautions

  • Use with caution in patients with renal impairment
  • Monitor for signs of allergic reactions
  • Consider alternative therapy in patients with a history of severe allergies

Pregnancy

Penicillins are generally considered safe to use during pregnancy; however, consult local guidelines and assess benefits versus risks.

Breast-feeding

Penicillins are excreted in breast milk in small amounts; generally considered safe, but monitor infant for possible effects.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Oral tablets
  • Oral suspension
  • Intravenous injection
  • Intramuscular injection

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: procaine

BNF-referenced

Procaine is a local anesthetic agent belonging to the ester group, primarily used for the production of local or regional anesthesia. It is particularly noted for its application in oral surgery, providing effective pain relief while also possessing the ability to constrict blood vessels, thereby reducing bleeding during procedures. Procaine is metabolized in the plasma, with a relatively short duration of action compared to some other local anesthetics.

Indications

  • Local anesthesia for dental procedures
  • Regional anesthesia
  • Minor surgical procedures

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing information.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Procaine acts mainly by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane of peripheral nerves. This inhibition prevents the generation of action potentials, thereby blocking signal conduction. Additionally, procaine has been shown to bind to and inhibit the function of N-methyl-D-aspartate (NMDA) receptors, nicotinic acetylcholine receptors, and the serotonin receptor-ion channel complex. It also reduces the permeability of resting nerve membranes to potassium ions.

Pharmacodynamics

As an anesthetic agent, procaine is indicated for producing local or regional anesthesia, particularly during dental procedures. Its unique property of vasoconstriction helps minimize bleeding. The anesthetic action develops progressively, leading to an increased threshold for electrical excitability, a decline in the rate of rise of action potentials, and a decreased probability of nerve impulse propagation.

Pharmacokinetics

Procaine is metabolized by the enzyme pseudocholinesterase in the plasma, undergoing hydrolysis to form para-aminobenzoic acid (PABA), which is subsequently excreted by the kidneys in urine. The pharmacokinetics of procaine involve a rapid onset of action but also a relatively short duration, necessitating careful consideration of dosing during procedures.

Adverse effects

  • Allergic reactions
  • Hypotension
  • Dizziness
  • Nausea
  • Vomiting
  • Tachycardia
  • Sedation

Interactions

  • Increased risk of CNS toxicity with other local anesthetics
  • Enhanced hypotensive effects with antihypertensive agents
  • Potential interaction with anticholinesterase agents

Precautions

  • Use with caution in patients with known hypersensitivity to procaine or other local anesthetics
  • Caution in patients with pre-existing cardiovascular or neurological conditions
  • Careful administration in elderly patients or those with compromised liver or kidney function

Pregnancy

Procaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult relevant guidelines.

Breast-feeding

Caution is advised when administering procaine to breastfeeding mothers due to potential excretion in breast milk.

Storage

Store at room temperature, protected from light and moisture. Ensure the vial is sealed when not in use.

Formulations

  • Procaine hydrochloride injection

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: dihydrostreptomycin

PubChem CID 439369

Molecular formula: C21H41N7O12

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

Molecular reference: penicillin

PubChem CID 2349

Molecular formula: C16H18N2O4S

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

Molecular reference: procaine

PubChem CID 4914

Molecular formula: C13H20N2O2

Mechanism of action

Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex. LOCAL ANESTHETICS BLOCK CONDUCTION BY DECREASING OR PREVENTING THE LARGE TRANSIENT INCREASE IN THE PERMEABILITY OF EXCITABLE MEMBRANES TO SODIUM IONS THAT NORMALLY IS PRODUCED BY A SLIGHT DEPOLARIZATION OF THE MEMBRANE. /LOCAL ANESTHETIC/ LOCAL ANESTHETICS BLOCK CONDUCTION IN NERVE PERHAPS BY COMPETING WITH CALCIUM @ SOME SITE THAT CONTROLS PERMEABILITY OF MEMBRANE. ... LOCAL ANESTHETICS ALSO REDUCE PERMEABILITY OF RESTING NERVE TO POTASSIUM AS WELL AS TO SODIUM IONS. /LOCAL ANESTHETICS/ AS THE ANESTHETIC ACTION PROGRESSIVELY DEVELOPS IN A NERVE, THE THRESHOLD FOR ELECTRICAL EXCITABILITY GRADUALLY INCREASES, THE RATE OF RISE OF THE ACTION POTENTIAL DECLINES, IMPULSE CONDUCTION SLOWS, & THE SAFETY FACTOR FOR CONDUCTION DECREASES; THESE FACTORS DECREASE THE PROBABILITY OF PROPAGATION OF THE ACTION POTENTIAL, AND NERVE CONDUCTION FAILS. /LOCAL ANESTHETICS/ POSTSYNAPTIC ACTION ... END-PLATE CURRENT IS MUCH PROLONGED BY PROCAINE. SIMILARLY, WHEN ... ADDED TO FLUID PERFUSING GANGLION, PREGANGLIONIC STIMULATION FAILS TO ELICIT POSTGANGLIONIC DISCHARGES & GANGLION CELLS BECOME INSENSITIVE TO STIMULATION BY ACETYLCHOLINE. IN ADDITION TO BLOCKING CONDITIONS IN NERVE AXONS IN THE PERIPHERAL NERVOUS SYSTEM, LOCAL ANESTHETICS INTERFERE WITH THE FUNCTION OF ALL ORGANS IN WHICH CONDUCTION OR TRANSMISSION OF IMPULSES OCCURS. ... EFFECTS ON ... CNS, THE AUTONOMIC GANGLIA, THE NEUROMUSCULAR JUNCTION, & ALL FORMS OF MUSCLE. /LOCAL ANESTHETICS/

Pharmacodynamics

Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.